EUVIMEDEUVIMED entdecken
Crossref

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System

Carlos Alberto da Silva Magliano iD, Ivan R Zimmermann iD, Leandro Jonata de Carvalho Oliveira iD, Marcia Gisele Santos da Costa, Tomás Reinert iD, Carlos Henrique Dos Anjos iD, Daniela D Rosa, Julio A P Araújo, Andrea K Shimada iD, Daniele Assad-Suzuki iD, Max S Mano iD, Gustavo Póvoa Dos Santos iD und 3 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-25-00245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Carlos Alberto da Silva Magliano und 14 weiteren Autor:innen. Beteiligte Einrichtung: Asas Avaliações Econômicas em Saúde Ltda, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adjuvant chemotherapy decisions for early-stage hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer remain challenging, requiring a balance between treatment efficacy and avoiding overtreatment. Gene expression signatures, such as the Oncotype DX assay, are valuable tools to predict recurrence risk and guide chemotherapy use. This study estimates the budget impact of incorporating the Oncotype DX test into clinical practice for patients with HR+/HER2– early-stage breast cancer in Brazil's private health care system. METHODS A budget impact analysis was performed using a hybrid decision tree-Markov model with transitions between recurrence-free survival, distant recurrence, acute myeloid leukemia, and death. The eligible population was derived from epidemiologic data. Subgroup analyses included node-negative (N0) patients stratified by age and clinical risk and node-positive (N1) patients stratified by menopausal status. The model assessed direct medical costs over 5 years without applying a discount rate. Two scenarios were analyzed: scenario 1, with progressive market uptake (40%-80% over 5 years), and scenario 2, with universal testing. RESULTS The introduction of the Oncotype DX test was associated with 5-year cost savings of approximately $19.3 million US dollars (USD; scenario 1) to $26.7 million USD (scenario 2). Incremental costs were observed only in N0 low-risk patients 50 years and younger ($9.5-$16.9 million USD) and premenopausal N1 patients ($2.2-$4.4 million USD). CONCLUSION Incorporating the Oncotype DX test is expected to optimize chemotherapy recommendations, reduce overtreatment, and generate cost savings in most subgroups. In Brazil's private health care system, the reduction in chemotherapy-related costs is anticipated to fully or partially offset the cost of testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleBrazilMiddle AgedBudgetsAdultNeoplasm StagingChemotherapy, AdjuvantAgedDelivery of Health Care

Autor:innen und Institutionen

  • Asas Avaliações Econômicas em Saúde Ltda, Rio de Janeiro, Brazil.
  • Universidade de Brasília, Distrito Federal, Brazil.
  • Oncoclinicas&CO-Medica Scientia InnovationResearch (MedSir), São Paulo, Brazil.
  • Hospital Nora Teixeira - Santa Casa de Porto Alegre, Porto Alegre, Brazil.
  • Hospital Sírio Libanês, São Paulo, Brazil.
  • Hospital Moinhos de Vento, Porto Alegre, Brazil.

ORCID-Profile: Carlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira, Tomás Reinert, Carlos Henrique Dos Anjos, Andrea K Shimada, Daniele Assad-Suzuki, Max S Mano, Gustavo Póvoa Dos Santos, Sergio Cordeiro de Oliveira, Virginia Areal

Zitieren

APA

da Silva Magliano, C. A., Zimmermann, I. R., Jonata de Carvalho Oliveira, L., Santos da Costa, M. G., Reinert, T., Dos Anjos, C. H., Rosa, D. D., P Araújo, J. A., K Shimada, A., Assad-Suzuki, D., S Mano, M., Póvoa Dos Santos, G., Cordeiro de Oliveira, S., Areal, V., & Millen, S. (2025). Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System. JCO Global Oncology. https://doi.org/10.1200/go-25-00245

Vancouver

da Silva Magliano CA, Zimmermann IR, Jonata de Carvalho Oliveira L, Santos da Costa MG, Reinert T, Dos Anjos CH, et al. Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System. JCO Global Oncology. 2025. doi:10.1200/go-25-00245

BibTeX
@article{daSilvaMagliano2025,
  author = {da Silva Magliano, Carlos Alberto and Zimmermann, Ivan R and Jonata de Carvalho Oliveira, Leandro and Santos da Costa, Marcia Gisele and Reinert, Tomás and Dos Anjos, Carlos Henrique and Rosa, Daniela D and P Araújo, Julio A and K Shimada, Andrea and Assad-Suzuki, Daniele and S Mano, Max and Póvoa Dos Santos, Gustavo and Cordeiro de Oliveira, Sergio and Areal, Virginia and Millen, Steve},
  title = {Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-25-00245}
}
Kostenlos starten →